000 04381nam a22005415i 4500
001 978-1-59745-470-4
003 DE-He213
005 20161121230842.0
007 cr nn 008mamaa
008 100301s2008 xxu| s |||| 0|eng d
020 _a9781597454704
_9978-1-59745-470-4
024 7 _a10.1007/978-1-59745-470-4
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
245 1 0 _aPrinciples of Molecular Oncology
_h[electronic resource] /
_cedited by Miguel H. Bronchud, Mary Ann Foote, Giuseppe Giaccone, Olufunmilayo Olopade, Paul Workman.
250 _aThird Edition.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2008.
300 _aXX, 420 p. 85 illus., 21 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aSelecting the Right Targets for Cancer Therapy -- Clinical Importance of Prognostic Factors -- Genetic Markers in Sporadic Tumors -- Genetic Markers in Breast Tumors with Hereditary Predisposition -- Circulating Tumor Markers -- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways -- Gene Expression Arrays for Pathway Analysis in Cancer Research -- Signaling Pathways in Cancer -- Estrogen Receptor Pathways and Breast Cancer -- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics -- Angiogenesis Switch Pathways -- Apoptosis Pathways and New Anticancer Agents -- Genomic Instability, DNA Repair Pathways and Cancer -- Epigenomics and Cancer -- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well? -- Aurora Kinases: A New Target for Anticancer Drug Development -- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways -- Suicide Gene Therapy -- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs -- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?.
520 _aDrawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a "disease process" involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics-expression profiling of genes and proteins- with developmental therapeutics, and the "binary state" concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between "information" and "knowledge," and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis.
650 0 _aMedicine.
650 0 _aCancer research.
650 0 _aMolecular biology.
650 0 _aHematology.
650 0 _aOncology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aHematology.
650 2 4 _aCancer Research.
650 2 4 _aMolecular Medicine.
700 1 _aBronchud, Miguel H.
_eeditor.
700 1 _aFoote, Mary Ann.
_eeditor.
700 1 _aGiaccone, Giuseppe.
_eeditor.
700 1 _aOlopade, Olufunmilayo.
_eeditor.
700 1 _aWorkman, Paul.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781934115251
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-59745-470-4
912 _aZDB-2-SME
950 _aMedicine (Springer-11650)
999 _c504906
_d504906